Discussing CAR T as an Early Treatment Option for B-Cell Lymphoma

This segment introduces the multidisciplinary panel featuring Caron A. Jacobson, MD, MMSc; Robb Friedman, MD (community hematologist-oncologist); and Alexandra E. Lynch, PA (physician assistant). The discussion centers on when community oncologists should initiate conversations about CAR T therapy with lymphoma patients during their treatment journey.

Dr Friedman emphasizes the importance of discussing CAR T therapy during the very first consultation with patients with newly diagnosed diffuse large B-cell lymphoma or follicular lymphoma. This early discussion helps patients understand their complete treatment pathway, including potential second-line options if initial chemotherapy fails or if they experience early recurrence within 12 months. By introducing CAR T therapy upfront, patients develop familiarity with this treatment option and understand they are supported by a comprehensive care system.

The panel acknowledges that some patients may initially resist traveling to specialized treatment centers, but early education helps overcome these barriers. Dr Jacobson supports this approach, noting that early discussion provides reassurance about multiple curative opportunities available to patients. This proactive communication strategy ensures patients understand all their treatment options from the beginning, reducing anxiety and improving treatment compliance when CAR T therapy becomes necessary.